

**Supplemental Table 1: Characteristics of the functional assays**

Assay N°	Assay subtype	Sample Volume (µL)	Purification EV	Blocking well	mAb Anti-TF reference	Control IgG	Coagulation factors	CaCl <sub>2</sub> (mM)	Substrate	Assay type	Analysis order	Reference
1	FXa generation	200	20,000 g for 15 min *2	mAb αTF, HTF-1, 10µg/mL	BD Biosciences Cat no: 550252	IgG1κ, MOPC-21, BD Biosciences, cat no: 554121) 10µg/mL	FX: 300nM FVIIa: 5nM	10	FXa substrate S-2765TM (Chromogenix)	Kinetic	A and B	/
2	FXa generation	100	20,000 g for 15 min *2	mAb αTF, HTF-1, 7.8µg/mL	BD Biosciences Cat no: 550252	IgG from mouse serum, Sigma Aldrich I5381	FX: 73.2nM FVIIa: 2.4nM	5	Pefachrome FXa 8595, 0.67 mmol/L	Endpoint	A and B	(Hisada & Mackman, 2019)
3	FXa generation	300	24,000 g for 60 min *2	mAb αTF, B4C9/SBTF1, 10µg/mL	Purified Mouse Anti-Human CD142, BioCytex-STAGO	IgG1, a-DNP 2H11–2H12, 10 µg/mL	FX: 190nM FVII: 10nM	5	CBS 31.39, STAGO	Kinetic	B and A	Adapted from (Vallier et al., 2019)
4	CY-QUANT MV-TF activity (RUO)	500	24,000 g for 60 min *2	mAb αTF, B4C9/SBTF1	Purified Mouse Anti-Human CD142, BioCytex-STAGO	IgG1, CeLLine, BioCytex	FX: 2200nM FVII: 0.31nM	10	Chromogenic anti-FXa 02.44, STAGO	Kinetic	B and A	Adapted from (Vallier et al., 2019)
5	CY-QUANT MV-TF activity (IMS)	100	IMS beads, 30 min	mAb αTF, B4C9/SBTF1	Purified Mouse Anti-Human CD142, BioCytex-STAGO	IgG1, CeLLine, BioCytex	FX: 2200nM FVII: 0.31nM	10	Chromogenic anti-FXa 02.44, STAGO	Kinetic	B and A	Adapted from (Franco et al., 2020)
6	FXa generation	500	20,000 g for 30 min 4°C *3	mAb αTF, HTF1, 200µg/mL	BD Biosciences Cat no: 550252	No	FX: 300nM FVIIa: 10nM	10	PN.A.PEP 1065, Cryopep	End point	B and A	Adapted from (Khorana et al., 2008)
7	FXa generation	200	18,000 g for 20 min *2	mAb αTF, HTF1	BD Biosciences Cat no: 550252	IgG from mouse serum, Sigma Aldrich I5381	FX: 73.2nM FVIIa: 2.4nM	10	Chromogenix S2765, Diapharma	End point	A and B	(Hisada & Mackman, 2019)
8	Zymuphen MP-TF	20	Microplate coated with anti-TF antibody	No	n.a.	No	Unknow	Yes	Factor Xa specific chromogenic substrate (CS 11(65))	Kinetic	/	According to the manufacturer's instructions

9	Zymuphen MP-TF	20	Microplate coated with anti-TF antibody	No	n.a.	No	Unknow	Yes	Factor Xa specific chromogenic substrate (CS 11(65))	Kinetic	/	According to the manufacturer's instructions
10	FXa generation	40	No	No	n.a.	No	Unknow	8	S2765	Parallel line model	/	/
11	FXa generation	Pellets from 300µL samples in 80µL and from 500µL samples in 140µL then 50µL used	16,000 g for 30 min *2	No	n.a.	No	FX: 150nM FVIIa: 5nM	5	Chromogenic substrate BIOPHEN CS-11(65), Hyphen-BioMed, 0,67mM	Absorption 405nm	/	Adapted from (Beckmann et al., 2022)
12	FXa generation	50	No	No	n.a.	No	FX: 73nM FVIIa: 2.4nM	5	Chromogenic CS-011(32) substrate	Absorption 410nm	/	Adapted from (Featherby et al., 2019)
13	Actichrome	All the pellet in 30µL and 25µL used. New freezing step	20,000 g for 70 min *2	No	n.a.	No	FX: 7nM FVIIa: 3.5nM	Yes	SPECTROZYME® FXa 5µM	Kinetic	/	According to the manufacturer's instructions
14	Actichrome	25	No	No	n.a.	No	FX: 7nM FVIIa: 3.5nM	Yes	SPECTROZYME® FXa 5µM	Kinetic	/	According to the manufacturer's instructions
15	Thrombin generation	300	20,000 g for 30 min	Human F VIIa Inactivated, Enzyme Research Laboratories, cat no: HFVIIai, 0.12µg/mL	n.a.	No	FX: 18.8nM FVIIa: 34pM FII: 130nM FV/Va: 4.8µg/mL	8.3	Pefachrome® FXa 8595 5-Diagnostics AG n°085-27	End point	A and B	(Østerud et al., 2022)
16	Thrombin generation CAT	EV Pellet resuspended in 200µL of EV-free plasma (2,500 g 15min twice and 20000 g 1h) and 20µL used for the assay	20,000 g for 60 min *2	mAb αTF, HTF-1, 7.84µg/mL	BD Biosciences Cat no: 550252	No	Standard plasma	Yes	7-amino-4methylcoumarin	Lag Time	B and A	(Kristensen & Nybo, 2023)
17	Thrombin generation	20	No	No	n.a.	No	Plasma Barium Sulfate Eluate	5	Chromogenic CS-01(81) substrate	Absorption 410nm	/	Adapted from (Ettelaie et al., 2008)
18	Clotting assay	90	No	mAb αTF, HTF-1, 30µg/ml	eBio-sciences Cat no : 17101152	No	n.a.	14	DO 405	½ Vmax (s)	B and A	(Berckmans et al., 2011)

Legend:

In the column intitled analysis order, the letter “A” means the conversion of raw data to U/mL and “B” means the subtraction of the value obtained using the anti-TF antibody from the value obtained using the control antibody.

Zymuphen manufacturer’s instruction: <https://www.coachrom.com/fileadmin/docs/hbm/en/521196.pdf>

Actichrome manufacturer’s instruction: [https://search.cosmobio.co.jp/cosmo\\_search\\_p/search\\_gate2/docs/BDX\\_/846.20180622.pdf](https://search.cosmobio.co.jp/cosmo_search_p/search_gate2/docs/BDX_/846.20180622.pdf)